The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): A pilot trial

Therapeutic Advances in Gastroenterology

Volumn 2, Issue 3, 2009, Pages 157-163

  Shields, William W ^a   Thompson, K E ^a   Harrison, S A ^b   Coyle, W J ^c  

^a NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^b BROOKE ARMY MEDICAL CENTER   (United States)

^c SCRIPPS CLINIC   (United States)

Author keywords

Histopathology; Insulin resistance; Metformin; NASH

Indexed keywords

METFORMIN; PLACEBO;

ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFICACY; EXERCISE; FEMALE; HUMAN; INSULIN RESISTANCE; LIVER BIOPSY; MALE; NONALCOHOLIC FATTY LIVER; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; WEIGHT REDUCTION;

EID: 77953368192     PISSN: 1756283X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1756283X09105462     Document Type: Article

References (25)

1. Adams, L.A., Zein, C.O., Angulo, P. and Lindor, K.D. (2004) A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol 99: 2365-2368.
2. Aithal, G.P., Thomas, J.A., Kaye, P.V., Lawson, A., Ryder, S.D., Spendlove, I. et al. (2008) Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 135: 1176-1184.
3. Angelico, F., Burattin, M., Alessandri, C., Del Ben, M., Lirussi, F. (2007) Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database of Systematic Reviews, CD00 5166.
4. Angulo, P. (2002) Nonalcoholic fatty liver disease. N Engl J Med 346: 1221-1231.
5. Bailey, C.J. and Turner, R.C. (1996) Metformin. N Engl J Med 334: 574-579.
6. Basaranoglu, M., Acbay, O. and Sonsuz, A. (1998) A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol 29: 495-501.
7. Belfort, R., Harrison, S.A., Brown, K., Darland, C., Finch, J., Hardies, J. et al. (2006) A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355: 2297-2307.
8. Browning, J.D., Szczepaniak, L.S., Dobbins, R., Nuremberg, P., Horton, J.D. et al. (2004) The prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology 40: 1387-1395.
9. Brunt, E.M., Janney, C.G., Di Bisceglie, A.M., Neuschwander-Tetri, B.A. and Bacon, B.R. (1999) Nonalcoholic steatohepatitis: A proposal for grading and staging the histologic lesions. Am J Gastroenterol 94: 2467-2474.
10. Bugianesi, E., Gentilcore, E., Manini, R., Natale, S., Vanni, E., Villanova, N. et al. (2005) A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 100: 1082-1090.
11. Bugianesi, E., Leone, N., Vanni, E., Marchesini, G., Brunello, F., Coracci, et al. (2002) Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123: 134-140.
12. Choudhury, J. (2004) Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease. Clin Liv Dis 8: 575-594.
13. Clark, J.M. (2006) Weight loss as a treatment for nonalcoholic fatty liver disease. J Clin Gastroenterol 40: S39-S43
14. Coyle, W.J. and Delaney, N. (1999) Metformin treatment in patients with nonalcoholic steatohepatitis normalizes LFTs and improves histology. Gastroenterology 116: L00 883(abstract).
15. Gomez-Dominguez, E., Gisbert, J.P., Moreno-Monteagudo, J.A., Garcia-Buey, L. and Moreno-Otero, R. (2006) A pilot study of atorvastatin treatment in dyslipidemic, non-alcoholic fatty liver patients. Aliment Pharmacol Ther 23: 1643-1647.
16. Hamaguchi, M., Kojima, T., Takeda, N., Nakagawa, T., Taniguchi, H., Fujii, K. et al. (2005) The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Int Med 143: 722-728.
17. Kleiner, D.E., Brunt, E.M., van Natta, M., Behling, C., Contos, M.J., Cummings, O.W. et al. (2005) Decision and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41: 1313-1321.
18. Lindor, K.D., Kowdley, K.V., Heathcote, E.J., Harrison, M.E., Jorgensen, R., Angulo, P. et al. (2004) Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 39: 770-778.
19. Loomba, R., Lutchman, G., Kleiner, D.E., Ricks, M., Feld, J.J. et al. (2009) Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 29: 172-182.
20. Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F. and Turner, R.C. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419.
21. McCullough, A.J. (2002) Update on nonalcoholic fatty liver disease. J Clin Invest 34: 255-262.
22. Reid, A.E. (2006) Nonalcoholic fatty liver disease. In: Feldman, M., Freidman, L. and Sleisenger, M. (eds) Sleisenger and Fordtran's Gastrointestinal and Liver Disease, 8th edn. Philadelphia: WB Saunders, 1793-1805.
23. Sanyal, A.J. (2002) AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 123: 1705-1725.
24. Sanyal, A.J., Mofrad, P.S., Contos, M.J., Sargeant, C., Luketic, V.A., Sterling, R.K. et al. (2004) A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastro Hepatol 2: 1107-1115.
25. Uygun, A., Kadayifici, A., Isik, A.T., Ozgurtas, T., Deveci, S., Tuzun, A. et al. (2004) Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 19: 537-544.